Microglial activation and β-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice

Journal of Neuroscience

Volumn 22, Issue 6, 2002, Pages 2246-2254

  Jantzen, Paul T ^a   Connor, Karen E ^a   DiCarlo, Giovanni ^a   Wenk, Gary L ^b   Wallace, John L ^c   Rojiani, Amyn M ^a   Coppola, Domenico ^a   Morgan, Dave ^a,d   Gordon, Marcia N ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Alzheimer's disease; MHC II; Microglia; NSAIDs; Transgenic mice; amyloid

Indexed keywords

3 [4 [2 FLUORO ALPHA METHYL (1,1' BIPHENYL) 4 ACETYLOXY] 3 METHOXYPHENYL] 2 PROPENOIC ACID 4 NITROXYBUTYL ESTER; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CELECOXIB; CONGO RED; FLURBIPROFEN; IBUPROFEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NCX 2216; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; PRESENILIN 1; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DEMENTIA; DRUG EFFECT; DRUG EFFICACY; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0037088914     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.22-06-02246.2002     Document Type: Article

References (75)

1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, et al (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21:383-421.
2. al Swayeh OA, Futter LE, Clifford RH, Moore PK (2000) Nitroparacetamol exhibits anti-inflammatory and anti-nociceptive activity. Br J Pharmacol 130:1453-1456.
3. Ard MD, Cole GM, Wei J, Mehrle AP, Fratkin JD (1996) Scavenging of Alzheimer's amyloid β-protein by microglia in culture. J Neurosci Res 43:190-202.
4. Bacskai BJ, Kajdasz ST, Christie RH, Carter, C, Games, D, Seubert, P, Schenk, D. Hyman B (2000) Anti-amyloid-β antibodies promote clearance of amyloid-β deposits imaged in vivo in PDAPP mice. Soc Neurosci Abstr 26:1059.
5. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, et al (2000) Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916-919.
6. Benzing WC, Wujek JR, Ward EK, Schaffer D, Ashe KH, Younkin SG, Brunden KR (1999) Evidence for glial-mediated inflammation in APPsw transgenic mice. Neurobiol Aging 20:581-590.
7. Brazil MI, Chung H, Maxfield FR (2000) Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia. J Biol Chem 275:16941-16947.
8. Breitner JC (1996) The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med 47:401-411.
9. Breitner JC (2000) Epidemiologic clues to the causes and routes to prevention of Alzheimer disease. J Neural Transm Suppl 59:251-254.
10. Chowdhary S, Townend JN (2001) Nitric oxide and hypertension: Not just an endothelium-derived relaxing factor! J Hum Hypertens 15:219-227.
11. Chung H, Brazil MI, Soe TT, Maxfield FR (1999) Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid β-peptide by microglial cells. J Biol Chem 274:32301-32308.
12. Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, Masdeu J, Kawas C, Aronson M, Wolfson L (1988) Clinico-pathological studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 38:1682-1687.
13. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR (1999) Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 58:376-388.
14. Del Soldato P, Sorrentino R, Pinto A (1999) NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol Sci 20:319-323.
15. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98:8850-8855.
16. DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D (2001) Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice. Neurobiol Aging 22:1007-1012.
17. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S (1996) Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature 383:710-713.
18. Fiorucci S, Santucci L, Cirino G, Mencarelli A, Familiari L, Soldato PD, Morelli A (2000) IL-1β-converting enzyme is a target for nitric oxide-releasing aspirin: New insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs. J Immunol 165:5245-5254.
19. Frackowiak J, Wisniewski HM, Wegiel J, Merz GS, Iqbal K, Wang KC (1992) Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce β-amyloid fibrils. Acta Neuropathol (Berl) 84:225-233.
20. Frautschy SA, Cole GM, Baird A (1992) Phagocytosis and deposition of vascular β-amyloid in rat brains injected with Alzheimer β-amyloid. Am J Pathol 140:1389-1399.
21. Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole GM (1998) Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 152:307-317.
22. Futter LE, al Swayeh OA, Moore PK (2001) A comparison of the effect of nitroparacetamol and paracetamol on liver injury. Br J Pharmacol 132:10-12.
23. Gordon MN, Schreier WA, Ou X, Holcomb LA, Morgan DG (1997) Exaggerated astrocyte reactivity after nigrostriatal deafferentation in the aged rat. J Comp Neurol 388:106-119.
24. Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Connor K, Melachrino JO, O'Callaghan JP, Morgan D (2002) Time course of the development of Alzheimer-like pathology in the doubly transgenic mPS1+mAPP mouse. Exp Neurol 173:183-195.
25. Graf E (1992) Antioxidant potential of ferulic acid. Free Radic Biol Med 13:435-448.
26. Grassi S, Pettorossi VE (2001) Synaptic plasticity in the medial vestibular nuclei: Role of glutamate receptors and retrograde messengers in rat brainstem slices. Prog Neurobiol 64:527-553.
27. Halliday GM, Shepherd CE, McCann H, Reid WG, Grayson DA, Broe GA, Kril JJ (2000) Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch Neurol 57:831-836.
28. Hauss-Wegrzyniak B, Vraniak P, Wenk GL (1999a) The effects of a novel NSAID on chronic neuroinflammation are age dependent. Neurobiol Aging 20:305-313.
29. Hauss-Wegrzyniak B, Willard LB, Del Soldato P, Pepeu G, Wenk GL (1999b) Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS. Brain Res 815:36-43.
30. Holcomb LA, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4:97-100.
31. Holcomb LA, Gordon MN, Benkovic SA, Morgan DG (1999a) Aβ and perlecan in rat brain. Glial activation, gradual clearance and limited neurotoxicity. Mech Ageing Dev 112:135-152.
32. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D (1999b) Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: Lack of association with amyloid deposits. Behav Gen 29:177-185.
33. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
34. James DS (1999) The multisystem adverse effects of NSAID therapy. J Am Osteopath Assoc 99:S1-S7.
35. Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19:312-318.
36. Kuo YM, Webster S, Emmerling MR, De Lima N, Roher AE (1998) Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of Aβ peptides of Alzheimer's disease. Biochim Biophys Acta 1406:291-298.
37. Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, Kalback WM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Roher AE (2001) Comparative analysis of amyloid-β chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem 276:12991-12998.
38. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20:5709-5714.
39. Lue L, Brachova L, Civin H, Rogers J (1996) Inflammation, Aβ deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol 55:1083-1088.
40. Mackenzie IR (1996) Antiinflammatory drugs in the treatment of Alzheimer's disease. J Rheumatol 23:806-808.
41. Mackenzie IR, Munoz DG (1998) Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 50:986-990.
42. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D (1996) Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F β-amyloid precursor protein and Alzheimer's disease. J Neurosci 16:5795-5811.
43. Matsuoka Y, Picciano M, Malester B, LaFrancois J, Zehr C, Daeschner JM, Olschowka JA, Fonseca MI, O'Banion MK, Tenner AJ, Lemere CA, Duff K (2001) Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am J Pathol 158:1345-1354.
44. McGeer EG, McGeer PL (1998) The importance of inflammatory mechanisms in Alzheimer disease. Exp Gerontol 33:371-378.
45. McGeer P, McGeer EG (2001) Inflammation, autotoxicity, and Alzheimer's disease. Neurobiol Aging 22:799-809.
46. McGowan E, Sanders S, Iwatsubo T, Takeuchi A, Saido T, Zehr C, Yu X, Uljon S, Wang R, Mann D, Dickson D, Duff K (1999) Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis 6:231-244.
47. Minghetti L, Polazzi E, Nicolini A, Greco A, Levi G (1999) Possible role of microglial prostanoids and free radicals in neuroprotection and neurodegeneration. Adv Exp Med Biol 468:109-119.
48. Moore S, Thanos S (1996) The concept of microglia in relation to central nervous system disease and regeneration. Prog Neurobiol 48:441-460.
49. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease Nature 408:982-985.
50. Napoli C, Ignarro LJ (2001) Nitric oxide and atherosclerosis. Nitric Oxide 5:88-97.
51. Napoli C, Cirino G, Del Soldato P, Sorrentino R, Sica V, Condorelli M, Pinto A, Ignarro LJ (2001) Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. Proc Natl Acad Sci USA 98:2860-2864.
52. Navarra P, Dello RC, Mancuso C, Preziosi P, Grossman A (2000) Gaseous neuromodulators in the control of neuroendocrine stress axis. Ann NY Acad Sci 917:638-646.
53. Paresce DM, Ghosh RN, Maxfield FR (1996) Microglial cells internalize aggregates of the Alzheimer's disease amyloid β-protein via a scavenger receptor. Neuron 17:553-565.
54. Prechel MM, Ding C, Washington RL, Kolodziej MS, Young MR (2000) In vivo indomethacin treatment causes microglial activation in adult mice. Neurochem Res 25:357-362.
55. Raine CS (2000) Inflammation in Alzheimer's disease: a view from the periphery. Neurobiol Aging 21:437-440.
56. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofiled C, Mansukhani L, Wilson P, Kogan F (1993) Clinical trail of indomethacin in Alzheimer's disease. Neurology 43:1609-1611.
57. Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, Shivers B, Walker D, McGeer P (1996) Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 17:681-686.
58. Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, Reardon IM, Zurcher-Neely HA, Heinrikson RL, Ball MJ (1993a) Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 268:3072-3083.
59. Roher AE, Palmer KC, Yurewicz EC, Ball MJ, Greenberg BD (1993b) Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J Neurochem 61:1916-1926.
60. Sasaki A, Yamaguchi H, Ogawa A, Sugihara S, Nakazato Y (1997) Microglial activation in early stages of amyloid β protein deposition. Acta Neuropathol (Berl) 94:316-322.
61. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, et al (1999) Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177.
62. Shaffer LM, Dority MD, Gupta-Bansal R, Frederickson RC, Younkin SG, Brunden KR (1995) Amyloid β protein (Aβ) removal by neuroglial cells in culture. Neurobiol Aging 16:737-745.
63. Snowdon DA (1997) Aging and Alzheimer's disease: Lessons from the Nun Study. Gerontologist 37:150-156.
64. Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M (1999) Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol 154:1673-1684.
65. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G (1994) Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 107:173-179.
66. Webster SD, Yang AJ, Margol L, Garzon-Rodriguez W, Glabe CG, Tenner AJ (2000) Complement component C1q modulates the phagocytosis of Aβ by microglia. Exp Neurol 161:127-138.
67. Webster SD, Galvan MD, Ferran E, Garzon-Rodriguez W, Glabe CG, Tenner AJ (2001) Antibody-mediated phagocytosis of the amyloid β-peptide in microglia is differentially modulated by C1q. J Immunol 166:7496-7503.
68. Wegiel J, Chauhan A, Wisniewski HM, Nowakowski J, Wang KC, Le Vine H (1996) Promotion of synthetic amyloid β-peptide fibrillization by cell culture media and cessation of fibrillization by serum. Neurosci Lett 211:151-154.
69. Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, O'Hare E, Esler WP, Maggio JE, Mantyh PW (1998) Fibrillar β-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci 18:2161-2173.
70. West M, Slomianka L, Gunderson H (1991) Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231:482-497.
71. Wilcock DM, Gordon MN, Ugen KE, Gottschall PE, DiCarlo G, Dickey C, Boyett KW, Jantzen PT, Connor KE, Melachrino J, Hardy J, Morgan D (2001) Number of Aβ inoculations in APP + PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol 20:731-736.
72. Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, Masliah E, Mucke L (2001) TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice Nat Med 7:612-618.
73. Yan JJ, Cho JY, Kim HS, Kim KL, Jung JS, Huh SO, Suh HW, Kim YH, Song DK (2001) Protection against β-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br J Pharmacol 133:89-96.
74. Young MR (1994) Eicosanoids and the immunology of cancer. Cancer Metastasis Rev 13:337-348.
75. Zicari A, Lipari M, Di Renzo L, Salerno A, Losardo A, Pontieri GM (1995) Stimulation of macrophages with IFN γ or TNF α shuts off the suppressive effect played by PGE2. Int J Immunopharmacol 17:779-786.